Printer Friendly

DOW CORNING 'FRUSTRATED' OVER FDA QUESTIONS ABOUT BREAST IMPLANT INFORMATION CENTER

 DOW CORNING 'FRUSTRATED' OVER FDA QUESTIONS
 ABOUT BREAST IMPLANT INFORMATION CENTER
 MIDLAND, Mich., Dec. 30 /PRNewswire/ -- Dow Corning today said that it was frustrated that the U.S. Food and Drug Administration should question the role of the Implant Information Center it established in July to help answer consumer questions about breast implants.
 "When we established the center we thought it was the human, compassionate thing to do," said J. Kermit Campbell, group vice president, U.S. Operations Dow Corning Corporation.
 The company said that they had received a letter from the FDA late today that asked the company to take steps to ensure that the Implant Information Center did not provide misleading information to callers.
 "We object strongly to anyone characterizing the Implant Information Center as anything but a source of accurate information," Campbell said. "The information our staff provides is taken directly from a booklet that has been reviewed with the FDA."
 "What the FDA is apparently objecting to is the kind of compassionate discussions that take place between the women on our staff and the thousands of callers who have been unduly alarmed by the inflammatory media coverage," Campbell said.
 "What the agency does not fully appreciate is that we have been providing a valuable service to thousands of women, whose call to us averages 40 minutes. With today's letter from the FDA, we may be forced simply to respond to these calls by distributing our written information, which we don't believe adequately meets the human need."
 "Spurred on by plaintiffs' attorneys and so-called public interest groups like Sidney Wolfe's Health Research Group, the media has reported only the sensationalistic, anecdotal side of the breast implant story which has unnecessarily frightened women across the country," Campbell said. "Rarely do we see stories about the hundreds of thousands of women who are totally satisfied with their implants."
 "We are shadow-boxing at the 11th hour with our critics who are free to say whatever they please, make whatever claims they choose without a shred of evidence, while we at Dow Corning are essentially ignored, having played the pioneering role in developing the device, and possessing more knowledge on the safety of this product than anyone," Campbell said.
 "This is another example of accusations made against us that are unfounded and give us little time to respond. It appears to us that this is part of a well-engineered effort to restrict the future availability of this important product to the women of this country."
 -0- 12/30/91
 /CONTACT: Bob Grupp, 517-496-6443, for Dow Corning/ CO: Dow Corning ST: Michigan IN: HEA SU:


PS -- NY048 -- 5793 12/30/91 22:46 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 30, 1991
Words:442
Previous Article:ZOLOFT, NEW PFIZER ANTIDEPRESSANT, GETS FDA APPROVAL; INTRODUCTION OF ZITHROMAX, NEW ANTIBIOTIC, DELAYED
Next Article:DELAWARE COURT AFFIRMS PARRETTI OUSTER FROM MGM
Topics:


Related Articles
DOW CORNING AND ITS EMPLOYEES CALL SAN FRANCISCO JURY AWARD REGARDING BREAST IMPLANTS 'OUTRAGEOUS'
DOW CORNING WELCOMES FDA REVIEW OF ADDITIONAL INFORMATION CONCERNING SILICONE BREAST IMPLANTS
DOW CORNING CALLS SID WOLFE CLAIMS '11TH HOUR SHADOWBOXING'
DOW CORNING WILL CONTINUE TO PROVIDE IMPLANT INFORMATION PACKAGE; TEMPORARILY SUSPENDS HOTLINE DISCUSSIONS
DOW CORNING TO RELEASE ALL DOCUMENTS SPECIFIED BY FDA
DOW CORNING ANNOUNCES $10 MILLION RESEARCH FUND TO CONTINUE STUDY OF SILICONE BREAST IMPLANT SAFETY
FIRST AND FINAL ADD TO DOW CORNING BREAST IMPLANTS.
DOW CORNING RELEASES INDEPENDENT INVESTIGATION RECOMMENDATIONS CONCERNING SILICONE BREAST IMPLANTS
Inamed Research Shows High Complication Rates and Autoimmune Symptoms for Breast Implant Patients; Poor Research Follow-up, Potentially Toxic Metals...
FDA Says Not Yet to Silicone Gel-Filled Breast Implants; ASAPS Survey Shows Doctors Mixed on Impact of Gel Availability.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters